In several preclinical studies, GLP-1 receptor agonists lowered the systemic levels of the pro-inflammatory cytokines, inhibited pro-inflammatory signaling pathways independent of glucose-lowering while concomitantly improving histological features of DKD [19]. This evidence concerns the gene GLP1R and diabetic kidney disease.